Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Undisclosed program
Obesity, Overweight, or Chronic Weight Management
Countdown
56days
Phase 2 readout · ~ Aug 31, 2026 estimated
What's at stake
Phase 2 trial results for Undisclosed program in Obesity, Overweight, or Chronic Weight Management are due ~ Aug 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 13h ago
“CT.gov NCT07169942: Phase 2 trial, sponsor Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Primary completion date 2026-08 (estimated).”